Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
11
US$ million (approximately ¥1.7 billion)Wording
Conditional
How definitive the wording is.This transaction
The Company's Investment in a FundCounterparty (target company)Allegis LS III 2026-10, a Series of CGF2021 LLC
Disclosing companyEXEDY Corporation
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Execution Date / Effective DateEnd of September 2026 (scheduled)
Target company
Investment in startups and related activities
Location Delaware, USADate of incorporation End of September 2026 (scheduled)
Consideration and expenses
Acquisition priceUS$11 million (approximately ¥1.7 billion)
Type of ConsiderationCash
Impact on Business Performance
The impact of this transaction on the Company's consolidated results is expected to be immaterial.
Procedures and assumptions
Management structure after acquisitionThe fund is expected to become a wholly owned subsidiary of the Company.
Total capital contributionUS$11 million (approximately ¥1.7 billion)
AdviserAllegis Capital
| Item | Details |
|---|---|
| Transaction name | The Company's Investment in a Fund |
| Counterparty name | Allegis LS III 2026-10, a Series of CGF2021 LLC |
| Name of the Subject Company | Allegis LS III 2026-10, a Series of CGF2021 LLC |
| Business Description of the Subject Company | Investment in startups and related activities |
| Location of the Subject Company | Delaware, USA |
| Date of Establishment of the Subject Company | End of September 2026 (scheduled) |
| Acquisition price | US$11 million (approximately ¥1.7 billion) |
| Type of Consideration | Cash |
| Voting rights ownership percentage | After 100% (before not disclosed) |
| Impact on Business Performance | The impact of this transaction on the Company's consolidated results is expected to be immaterial. |
| Execution Date / Effective Date | End of September 2026 (scheduled) |
| Management structure after acquisition | The fund is expected to become a wholly owned subsidiary of the Company. |
| Total capital contribution | US$11 million (approximately ¥1.7 billion) |
| Adviser | Allegis Capital |
Items this document does not state (20)
Capital Stock of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To pursue collaboration with startups aimed at enhancing corporate value over the medium to long term, invest through the fund in startup companies with potential for collaboration, and launch and expand new businesses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.